Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 2

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Genitourinary 1CNS 1

Conditions

Stomach Neoplasms 2Rectal Neoplasms 1Osteoarthritis 1Colorectal Neoplasms 1Colonic Neoplasms 1Cancer Pain 1Barrett Esophagus 1Adenomatous Polyposis Coli 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 329Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 258lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
rofecoxib × Gastrointestinal × Clear all
NCT00140894 2019-09-20

A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

Merck Sharp & Dohme LLC

Phase 4 Terminated
62 enrolled
Gastrointestinal

Cancer Pain, Osteoarthritis, Adenomatous Polyposis Coli

NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00637988 2011-01-21

Barrett's Esophagus - 315 - 3 Way Cross Over

AstraZeneca

Phase 4 Completed
32 enrolled
Gastrointestinal

Barrett Esophagus

NCT00165048 2005-12-09

Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
206 enrolled
Gastrointestinal

Stomach Neoplasms

NCT00164892 2005-11-17

Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

Chinese University of Hong Kong

Phase 3 Unknown
214 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡